Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Telix Pharmaceuticals Limited due to allegations of violations of federal securities laws, specifically regarding misleading statements about the company's prostate cancer therapeutic candidates and supply chain quality [2][4]. Group 1: Legal Investigation and Class Action - The firm is encouraging investors who suffered losses in Telix between February 21, 2025, and August 28, 2025, to discuss their legal rights and options [1]. - A federal securities class action has been filed against Telix, with a deadline of January 9, 2026, for investors to seek the role of lead plaintiff [2]. - The lead plaintiff is defined as the investor with the largest financial interest in the relief sought, who will oversee the litigation on behalf of the class [7]. Group 2: Allegations Against Telix - The complaint alleges that Telix and its executives made false and misleading statements regarding the progress of prostate cancer therapeutic candidates and the quality of its supply chain [4]. - On July 22, 2025, Telix disclosed receiving a subpoena from the U.S. Securities and Exchange Commission, leading to a more than 13% drop in the price of its American Depositary Shares over two trading sessions [5]. - On August 28, 2025, Telix revealed it received a Complete Response Letter from the U.S. Food and Drug Administration for its product TLX250-CDx, which identified deficiencies in the Chemistry, Manufacturing, and Controls package, resulting in a more than 21% decline in share price over two trading sessions [6].

Core Viewpoint - Montelukast, once regarded as a "cough remedy," is now under scrutiny due to its psychiatric side effects, leading to a shift in its usage from a widely accepted treatment to one that requires careful evaluation and cautious application [1][10]. Regulatory Changes - The National Medical Products Administration (NMPA) has revised the drug's labeling to include warnings about potential severe adverse reactions such as depression and suicidal tendencies, advising immediate cessation and medical consultation if symptoms arise [2][4]. Usage Patterns - Despite the warnings, Montelukast is still widely used for common symptoms like cough and rhinitis, with the original drug "Singulair" selling over 2 million boxes on a single platform [1][10]. - A study indicated that only 13.88% of prescriptions for Montelukast adhered to its approved indications, with off-label use reaching 86.12%, particularly for conditions like Chronic Obstructive Pulmonary Disease (COPD) and bronchitis [5][6]. Market Dynamics - There are over 60 approved Montelukast products in China, produced by numerous companies, indicating a significant market presence [8]. - The tightening of prescription practices has led to a shift in clinical attitudes, with doctors now requiring clear therapeutic necessity and informed consent from parents before prescribing Montelukast, especially for children [10][11]. Patient Concerns - Many families face a dilemma between the drug's cough-relief efficacy and its associated risks, leading to increased anxiety about treatment options [2][10]. - There is a growing recognition among the public that Montelukast should not be viewed as a universal "cough remedy," but rather as a medication that requires careful assessment and clear communication of risks [11].

U.S. financial markets are observing a full closure today, Thursday, December 25, 2025, in celebration of the Christmas holiday. Trading on both the New York Stock Exchange (NYSE) and Nasdaq is suspended for the entire day, with normal operations set to resume on Friday, December 26, 2025. This pause follows a shortened, yet record-setting, trading session on Christmas Eve, Wednesday, December 24, where major indexes continued their upward trajectory, fueling hopes of a "Santa Claus rally" to close out the ...

BofA raised the firm’s price target on Agios Pharmaceuticals (AGIO) to $34 from $32 and keeps a Buy rating on the shares following FDA approval for mitapivat to make it the only drug approved in both transfusion-dependent and non-transfusion-dependent alpha- or beta- thalassemia. The REMS and black box for hepatocellular injury were in line with the firm’s expectations and BofA doesn’t expect this to impact uptake, the analyst tells investors. Claim 70% Off TipRanks This Holiday Season Published first on ...

Core Viewpoint - The National Medical Products Administration (NMPA) of China has mandated the addition of warnings regarding neuropsychiatric adverse reactions in the instructions for Montelukast formulations, including serious reactions such as depression and suicidal tendencies, with a deadline for compliance set for March 12, 2026 [1][4]. Group 1: Regulatory Changes - The NMPA requires all Montelukast product license holders in China to revise their product instructions to include warnings about neuropsychiatric adverse reactions [1]. - The revisions must be submitted to the NMPA or provincial drug regulatory departments by March 12, 2026, and all existing product labels must be updated within nine months after the submission [1]. Group 2: Market Context - Montelukast sodium, originally developed by Merck (brand name: Singulair), is a potent selective leukotriene receptor antagonist used for asthma prevention and treatment in children aged 2 to 14 [3]. - Following the expiration of Merck's patent, domestic companies have begun to produce generic versions, with 62 approvals found on the NMPA website from various manufacturers [3]. Group 3: Adverse Reactions and Clinical Implications - The revision of Montelukast's instructions is based on adverse reaction assessments, with the FDA in the U.S. having previously issued a black box warning for similar neuropsychiatric adverse reactions [4][5]. - Reports of adverse reactions, including depression and suicidal behavior, have been documented, with a study indicating that 86.12% of Montelukast prescriptions in a certain hospital were for off-label uses [5][8]. Group 4: Sales and Competitive Landscape - Montelukast ranked third in sales among asthma medications in China for the first three quarters of 2024, with total sales reaching 1.33 billion yuan [9]. - The competitive landscape includes 24 companies with 42 formulations of Montelukast available, with significant market shares held by companies like Eurofarma and Shanghai Anbisen [9]. Group 5: Emerging Treatments - The emergence of biologic therapies is changing the treatment landscape for pediatric asthma, with several new biologics approved for use in children [10]. - The NMPA's revisions to Montelukast's labeling serve as a reminder for the need for safe and effective prescribing practices as new treatment options become available [10].

Company Overview - Beximco Pharmaceuticals is a leading manufacturer and exporter of medicines based in Bangladesh, incorporated in 1976 [2] - The company initially imported products from Bayer, Germany, and Upjohn, USA, before starting its own manufacturing in 1980 under licensing arrangements [2] - Beximco Pharma launched its own formulation brands in 1983 and has been committed to providing access to contemporary medicines globally [2] Stock Performance - Beximco Pharmaceuticals' stock increased by 5.9%, with shares last traded at GBX 45 [1][4] - The stock crossed above its fifty-day moving average of GBX 41.80 during trading, reaching a high of GBX 45 [4] - The company has a market capitalization of £200.75 million and a price-to-earnings ratio of 0.03 [1] Financial Ratios - Beximco Pharmaceuticals has a debt-to-equity ratio of 12.47, indicating a high level of debt compared to equity [1] - The current ratio stands at 2.13, suggesting good short-term financial health, while the quick ratio is at 0.37 [1] - The fifty-day moving average price is GBX 41.80, and the two-hundred-day moving average price is GBX 42.40 [1]

Group 1 - Pfizer Inc. is currently viewed as a high-volume stock to consider for investment, despite a recent price target reduction from Bank of America to $27 from $28, maintaining a Neutral rating [1] - The company's 2026 guidance indicates a more significant decline in its COVID-19 franchise than previously expected, prompting a revision of near-term financial forecasts [1] - Attention is now directed towards Pfizer's obesity strategy, with investors anticipating trial results from the recently acquired Metsera assets to assess their potential in the weight-loss market [1] Group 2 - Pfizer and Astellas reported positive topline results from the Phase 3 EV-304 trial, demonstrating that the combination of PADCEV and Keytruda significantly enhances event-free survival and overall survival for muscle-invasive bladder cancer patients [2] - The trial also achieved its secondary endpoint of pathologic complete response rate, indicating a statistically significant improvement over traditional neoadjuvant chemotherapy [3] - The findings from the EV-304 trial, along with earlier results from the EV-303 trial, position the PADCEV and Keytruda combination as a potential new standard of care for muscle-invasive bladder cancer patients, regardless of cisplatin eligibility [3]

【环球网财经综合报道】2025年A股IPO市场交出了一份亮眼的成绩单，同时也展现了鲜明的结构性变 化。最新统计数据显示，截至12月22日，年内A股发行上市家数共计106家，同比增长9.28%；募资总额 却高达1190.83亿元，同比激增91.23%。募资增速远超数量增速，直观反映出今年IPO市场"少而精"的特 征——超大型项目的密集落地成为募资规模跳涨的关键动力，这与A股从"规模扩张"向"质量优先"的转 型高度契合。 随着IPO市场的活跃，券商投行格局也迎来重塑。年内共有30家券商斩获A股IPO项目，保荐承销费用合 计60.03亿元，同比增长38.03%。值得注意的是，国泰君安与海通证券合并后的"国泰海通"效应显现， 以17家的保荐数量位居行业第一，超过中信证券。而在募资规模和承销费率方面，头部券商依然展现出 强大优势，中金公司以平均每单47.91亿元的募资额居首，华泰联合则以266.74亿元的实际募资规模排名 榜首。与此同时，大额项目也带来了承销费率的差异化，中金公司、华泰联合等大券商的平均承销费率 相对较低。 监管层面的变化同样值得关注。年内IPO终止审查企业共计107家，同比大幅减少75.34%。终止数 ...

（来源：河北新闻网） 转自：河北新闻网 位于石家庄市国际生物医药园的绿叶嘉奥制药石家庄有限公司，工作人员正在进行设备的调试。 塔吊挥动长臂，厂房拔节生长，运输车辆往来穿梭，实验室里灯火通明……位于石家庄高新区的石家庄市国际生物医药园里，扑面而来的是项 目建设的火热气息与产业集聚的蓬勃活力。 创新沃土蓄发展势能，项目建设现场酣畅淋漓。目前，生物医药园汇聚了300余家企业，初步形成龙头企业引领、中型企业支撑、小微企业蓬 勃发展的良好生态。进入四季度以来，园区正以"冲刺"之姿，全力打好年度收官战，推动更多实验室技术走向生产线，为高质量发展持续注入 新动能。 优质项目串珠成链 绿叶嘉奥是高新区引进生物医药园的一家创新药研发企业，通过"资本运作、基金支持、以投代补"的方式，他们与政府合作共建项目。结合项 目引进和落地建设实际，高新区建立协同高效的项目入区评审和开展项目包联服务，绘制了招商引资项目入区落地流程图，以专家论证会、项 目小组会等形式，严把项目入区关，提高了生物医药园入园项目的质量。 发展活力，来源于一个个项目的扎实推进。 今年以来，高新区共引进生物医药类项目59个，依托生物医药园打造的良好发展环境，让更多企业 ...

Market Overview - U.S. equities have experienced a rebound, particularly in AI-related stocks, following a selloff due to concerns over inflated valuations and high capital expenditures impacting profits [1][11] - Major indexes recorded their fifth consecutive session of gains, with the Dow Jones Industrial Average rising by 288.75 points (0.60%) to 48,731.16, the S&P 500 gaining 22.26 points (0.32%) to 6,932.05, and the Nasdaq Composite increasing by 51.46 points (0.22%) to 23,613.31 [2][11] Economic Indicators - Recent data indicated a resilient economy, with new applications for U.S. jobless benefits unexpectedly falling last week [1][11] - The market is currently pricing in approximately 50 basis points of rate cuts from the Federal Reserve for the next year, although expectations for a January cut are low [1][11] Sector Performance - Financials were among the best-performing sectors in the S&P 500, with a gain of 0.5%, while the energy index was the only sector to close in negative territory [7][11] - Bank stocks contributed to the overall market gains, supporting the bullish sentiment [11] Notable Company Movements - Nike shares increased by 4.6% after Apple CEO Tim Cook purchased approximately $3 million worth of shares [9][11] - Dynavax Technologies surged by 38.2% following an announcement that French drugmaker Sanofi would acquire the company for around $2.2 billion (1.9 billion euros) [10][11] - Intel shares decreased by 0.5% after reports that Nvidia halted tests for manufacturing chips using Intel's 18A production process [9][11] Market Sentiment - The recent gains in U.S. stocks have led to speculation about a "Santa Claus rally," a seasonal trend where the S&P 500 typically posts gains during the last five trading days of the year and the first two in January [7][11] - Wall Street's "fear gauge" remains at levels not seen since December 2024, yet the bull market, which began in October 2022, continues to thrive due to optimism surrounding AI, potential rate cuts, and a resilient economy [9][11]